Major Extremity Trauma Research Consortium Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Baltimore MD United States (2009)

Organization Overview

First Clinical Trial
2013
NCT01789216
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Major Extremity Trauma Research Consortium

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Fractures, Bone (Phase 3)

Infections (Phase 3)

Surgical Wound Infection (Phase 3)

Thrombosis (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 8